Next Article in Journal
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
Next Article in Special Issue
Targeted Therapy of Cancer Using Photodynamic Therapy in Combination with Multi-faceted Anti-Tumor Modalities
Previous Article in Journal
A Review of Anti-Inflammatory Drug-Induced Gastrointestinal Injury: Focus on Prevention of Small Intestinal Injury
Previous Article in Special Issue
Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait
Open AccessReview

New Trends in Cancer Therapy: Targeting Ion Channels and Transporters

Department of Experimental Pathology and Oncology, University of Florence, Italy
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Italy
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(4), 1202-1224;
Received: 16 February 2010 / Revised: 25 March 2010 / Accepted: 29 March 2010 / Published: 20 April 2010
(This article belongs to the Special Issue Targeted Therapy)
The expression and activity of different channel types mark and regulate specific stages of cancer establishment and progression. Blocking channel activity impairs the growth of some tumors, both in vitro and in vivo, which opens a new field for pharmaceutical research. However, ion channel blockers may produce serious side effects, such as cardiac arrhythmias. For instance, Kv11.1 (hERG1) channels are aberrantly expressed in several human cancers, in which they control different aspects of the neoplastic cell behaviour. hERG1 blockers tend to inhibit cancer growth. However they also retard the cardiac repolarization, thus lengthening the electrocardiographic QT interval, which can lead to life-threatening ventricular arrhythmias. Several possibilities exist to produce less harmful compounds, such as developing specific drugs that bind hERG1 channels in the open state or disassemble the ion channel/integrin complex which appears to be crucial in certain stages of neoplastic progression. The potential approaches to improve the efficacy and safety of ion channel targeting in oncology include: (1) targeting specific conformational channel states; (2) finding ever more specific inhibitors, including peptide toxins, for channel subtypes mainly expressed in well-identified tumors; (3) using specific ligands to convey traceable or cytotoxic compounds; (4) developing channel blocking antibodies; (5) designing new molecular tools to decrease channel expression in selected cancer types. Similar concepts apply to ion transporters such as the Na+/K+ pump and the Na+/H+ exchanger. Pharmacological targeting of these transporters is also currently being considered in anti-neoplastic therapy. View Full-Text
Keywords: oncology; hERG; Kv11; Kv10; glioma; leukemia; Na+/K+ ATPase; side effects oncology; hERG; Kv11; Kv10; glioma; leukemia; Na+/K+ ATPase; side effects
Show Figures

Figure 1

MDPI and ACS Style

Arcangeli, A.; Becchetti, A. New Trends in Cancer Therapy: Targeting Ion Channels and Transporters. Pharmaceuticals 2010, 3, 1202-1224.

AMA Style

Arcangeli A, Becchetti A. New Trends in Cancer Therapy: Targeting Ion Channels and Transporters. Pharmaceuticals. 2010; 3(4):1202-1224.

Chicago/Turabian Style

Arcangeli, Annarosa; Becchetti, Andrea. 2010. "New Trends in Cancer Therapy: Targeting Ion Channels and Transporters" Pharmaceuticals 3, no. 4: 1202-1224.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop